Review of Gardasil

Journal of Vaccines and Vaccination

Volumn 1, Issue 3, 2010, Pages

  Harper, Diane M ^a   Vierthaler, Stephen L ^a   Santee, Jennifer A ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Adverse effects; Cervical cancer; Duration of efficacy; Gardasil; HPV vaccine immunology

Indexed keywords

EID: 84858817324     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000107     Document Type: Review

References (78)

1. National Toxicology Program (2005) NTP 11th Report on Carcinogens. Rep Carcinog 11: 1-A32.
2. Zur Hausen H (2009) Papillomaviruses in the causation of human cancers-a brief historical account. Virology 384: 260-265.
3. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
4. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, et al. (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7: 453-459.
5. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, et al. (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072-1079.
6. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, et al. (2007) Prevalence of HPV Infection among females in the United States. JAMA 297: 813-819.
7. Schiffman M, Rodríguez AC (2008) Heterogeneity in CIN3 diagnosis. Lancet Oncol 9: 404-406.
8. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, et al. (2008) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9: 425-434.
9. Cubie HA, Plumstead M, Zhang W, de Jesus O, Duncan LA, et al. (1998) Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11-13-year-old schoolgirls. J Med Virol 56: 210-216.
10. Schiffman M, Kjaer SK (2003) Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31: 14-19.
11. Rintala MA, Grénman SE, Järvenkylä ME, Syrjänen KJ, Syrjänen SM (2005) High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study. Clin Infect Dis 41: 1728-1733.
12. Smith EM, Ritchie JM, Yankowitz J, Swarnavel S, Wang D, et al. (2004) Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission. Sex Transm Dis 31: 57-62.
13. Smith EM, Johnson SR, Ritchie JM, Feddersen D, Wang D, et al. (2004) Persistent HPV infection in postmenopausal age women. Int J Gynaecol Obstet 87: 131-137.
14. Bandyopadhyay S, Sen S, Majumdar L, Chatterjee R (2003) Human papillomavirus infection among Indian mothers and their infants. Asian Pac J Cancer Prev 4: 179-184.
15. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, et al. (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186: 1396-402.
16. Dunne EF, Karem KL, Sternberg MR, Stone KM, Unger ER, et al. (2005) Seroprevalence of human papillomavirus type 16 in children. J Infect Dis191: 1817-1819.
17. http://apps.nccd.cdc.gov/uscs/cancersbyraceandethnicity.aspx [accessed 20 Nov 2010]
18. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, et al. (2006) Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modeling analyses. PLoS Med 3: e138.
19. Harper DM (2009) Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 8: 1663-1679.
20. Berkhof J, Bogaards J, Coupé V, Meijer C (2010) Modeling the influence of screening uptake on the future incidence of cervical cancer and the costeffectiveness of HPV vaccination. Abstract number 464. 26th International Papillomavirus Conference. July 3-8, Montreal Canada.
21. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al.(2010) Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPVassociated genital diseases in young women. J Natl Cancer Inst 102: 325-339.
22. Sutton I, Lahoria R, Tan I, Clouston P, Barnett M (2009) CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15: 116-119.
23. Klein SL, Jedlicka A, Pekosz A (2010) The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 10: 338-349.
24. Stanley M (2006) Immune responses to human papillomavirus. Vaccine 24 Suppl 1:S16-22.
25. Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, et al (2010) Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 102: 315-324.
26. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, et al. (2000) Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 181: 1911-1919.
27. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428.
28. Olsson WE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 5: 696-704.
29. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, et al. (2007) Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2: 4931-4939.
30. Michaels KB, Zur Hausen H (2009) HPV vaccine for all. Lancet 374: 268-270.
31. Kim JJ, Goldie SJ (2008) Health and economic implication of HPV vaccination in the United States. N Engl J Med 359: 821-832.
32. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928-1943.
33. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111274.pdf
34. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190978.pdf.
35. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, et al. (2011) Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. N Engl J Med 364: 401-411.
36. Palefsky J (2010) Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. Abstract 465. Presented at 2010 HPV International Papillomavirus Conference, July 3-8, Montreal, Canada.
37. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645-1651.
38. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278.
39. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, et al. (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24: 5571-5583.
40. Koutsky LA for the FUTURE II Study Group (2007) Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Engl J Medicine 356: 1915-1927.
41. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, et al. (2006) Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118: 2135-2145.
42. Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, et al. (2010) Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16 and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 29: 95-101.
43. Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, et al. (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373: 1949-1957.
44. Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, et al. (2008) Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26: 686-696.
45. Reisinger KS, Block SL, Collins-Ogle M, Marchant C, Catlett M, et al. (2010) Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel. Pediatrics 125: 1142-1151.
46. Vesikari T, Van Damme P, Lindblad N, Pfletschinger U, Radley D, et al. (2010) An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 29: 314-318.
47. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, et al. (2009) Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 114: 1179-1188.
48. Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, et al. (2009) Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 114: 1170-1178.
49. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, et al. (2009) Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302: 750-757.
50. Blitshteyn S (2010) Postural tachycardia syndrome after vaccination with Gardasil. Eur J Neurol 17: e52.
51. Vandenbroucke JP (2001) In defense of case reports and case series. Ann Intern Med 134: 330-334.
52. Vandenbroucke JP (2006) Case reports of suspected adverse drug reactions: Case reports were dismissed too quickly. BMJ 332: 488.
53. Agha R, Rosin RD (2010) Time for a new approach to case reports. Int J Surg 8: 330-332.
54. Centers for Disease Control and Prevention (CDC) (2008) Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 57: 457-460.
55. Kang LW, Crawford N, Tang ML, Buttery J, Royle J, et al. (2008) Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ 337: a2642.
56. Debeer P, De Munter P, Bruyninckx F, Devlieger R (2008) Brachial plexus neuritis following HPV vaccination. Vaccine 26: 4417-4419.
57. Lower J (2008) Two unclear cases of death. Can we still recommend HPV vaccination? MMW Fortschr Med 150: 6.
58. Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, et al. (2008) Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 32: 371-387.
59. Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C, et al. (2009) Acute disseminated encephalomyelitis following vaccination against human papillomavirus. Neurology 72: 2132-2133.
60. McCarthy JE, Filiano J (2009) Opsoclonusmyoclonus after human papilloma virus vaccine in a pediatric patient. Parkinsonism Relat Disord 15(10):792-794.
61. Cohen SM (2009) Multiple Evanescent White Dot Syndrome After Vaccination for Human Papilloma Virus and Meningococcus. J Pediatr Ophthalmol Strabismus 25: 1-3.
62. Khalifa YM, Monahan PM, Acharya NR (2010) Ampiginous choroiditis following quadrivalent human papilloma virus vaccine. Br J Ophthalmol 94: 137-139.
63. Ojaimi S, Buttery JP, Korman TM (2009) Quadrivalent human papillomavirus recombinant vaccine associated lipoatrophy. Vaccine 27: 2876-2878.
64. Marsee DK, Williams JM, Velazquez EF (2008) Aluminum granuloma after administration of the quadrivalent human papillomavirus vaccine. Report of a case. Am J Dermatopathol 30: 622-624.
65. Studdiford J, Lamb K, Horvath K, Altshuler M, Stonehouse A (2008) Development of unilateral cervical and supraclavicular lymphadenopathy after human papillomavirus vaccination. Pharmacotherapy 28: 1194-1197.
66. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, et al. (2008) Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 179: 525-533.
67. Das A, Chang D, Biankin AV, Merrett ND (2008) Pancreatitis following human papillomavirus vaccination. Med J Aust 189: 178.
68. Pugnet G, Ysebaert L, Bagheri H, Montastruc JL, Laurent G (2009) Immune thrombocytopenia purpura following human papillomavirus vaccination. Vaccine 27: 3690.
69. Katoulis AC, Liakou A, Bozi E, Theodorakis M, Alevizou A, et al. (2010) Erythema multiforme following vaccination for human papillomavirus. Dermatology 220: 60-62.
70. http://whqlibdoc.who.int/aide-memoire/a87773_eng.pdf [accessed 20 Nov 2010].
71. Centers for Disease Control and Prevention (CDC) (2010) Preliminary Results: Surveillance for Guillain-Barré Syndrome after Receipt of Influenza A (H1N1) 2009 Monovalent Vaccine-United States, 2009--2010. MMWR Morb Mortal Wkly Rep 59: 657-661.
72. http://www.hrsa.gov/vaccinecompensation/statistics_report.htm#claims_filed [accessed 20 Nov 2010].
73. http://clinicaltrials.gov/ct2/results?term=Gardasil+ [accessed 20 Nov 2010].
74. Coupe VMH, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, et al. (2009) HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Modelbased cost-effectiveness. Int J Cancer 124: 970-978.
75. Pegler S, Underhill J (2010) Evaluating the Safety and Effectiveness of New Drugs. Am Fam Physician 82: 53-57.
76. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, et al. (2009) Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 27: 5612-5619.
77. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459-1466.
78. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111287.pdf-[accessed 20 Nov 2010].